Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Net Margin (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Net Margin for 5 consecutive years, with 114.97% as the latest value for Q3 2025.

  • For Q3 2025, Net Margin changed N/A year-over-year to 114.97%; the TTM value through Sep 2025 reached 144.83%, changed N/A, while the annual FY2022 figure was 8697.64%, 729747.0% down from the prior year.
  • Net Margin hit 114.97% in Q3 2025 for Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
  • Across five years, Net Margin topped out at 114.97% in Q3 2025 and bottomed at 21604.84% in Q1 2021.
  • Average Net Margin over 3 years is 4222.73%, with a median of 1826.16% recorded in 2022.
  • Year-over-year, Net Margin crashed -1960997bps in 2021 and then surged 1977868bps in 2022.
  • Cyclerion Therapeutics' Net Margin stood at 2690.06% in 2021, then plummeted by -63bps to 4389.87% in 2022, then skyrocketed by 97bps to 114.97% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 114.97%, 1797.85%, and 1798.77% for Q3 2025, Q2 2025, and Q1 2025 respectively.